Key Points
- Ai Biotechnology LLC bought 2,000,000 shares of Zura Bio on Feb. 26 at $6.25 per share (a $12.5M purchase), boosting its direct stake to 6,552,725 shares — a 43.93% increase valued at about $40.95M.
- Zura opened at $6.76 (up ~2.1%), has a market cap of ~$439.5M and 61.14% institutional ownership, and analyst coverage is mixed but averages a Moderate Buy with an $11.60 price target.
Zura Bio Limited (NASDAQ:ZURA - Get Free Report) major shareholder Ai Biotechnology Llc acquired 2,000,000 shares of the firm's stock in a transaction dated Thursday, February 26th. The stock was bought at an average price of $6.25 per share, with a total value of $12,500,000.00. Following the purchase, the insider directly owned 6,552,725 shares in the company, valued at approximately $40,954,531.25. This trade represents a 43.93% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.
Zura Bio Stock Up 2.1%
Shares of Zura Bio stock opened at $6.76 on Tuesday. Zura Bio Limited has a 52-week low of $0.97 and a 52-week high of $7.19. The company has a market capitalization of $439.54 million, a P/E ratio of -10.40 and a beta of 0.18. The company has a 50 day moving average of $5.73 and a 200 day moving average of $4.11.
Hedge Funds Weigh In On Zura Bio
A number of hedge funds and other institutional investors have recently bought and sold shares of ZURA. Seven Fleet Capital Management LP acquired a new position in shares of Zura Bio during the 4th quarter worth $872,000. XTX Topco Ltd purchased a new position in shares of Zura Bio in the fourth quarter valued at $348,000. Suvretta Capital Management LLC increased its position in shares of Zura Bio by 1.7% in the fourth quarter. Suvretta Capital Management LLC now owns 5,567,001 shares of the company's stock valued at $29,171,000 after buying an additional 94,110 shares in the last quarter. Quadrature Capital Ltd acquired a new position in shares of Zura Bio during the 4th quarter worth $192,000. Finally, Millennium Management LLC boosted its position in shares of Zura Bio by 75.1% in the 4th quarter. Millennium Management LLC now owns 1,032,680 shares of the company's stock worth $5,411,000 after buying an additional 442,980 shares in the last quarter. 61.14% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
ZURA has been the topic of a number of recent analyst reports. Leerink Partners upgraded Zura Bio to a "strong-buy" rating in a report on Sunday, November 23rd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Zura Bio in a research note on Friday, January 9th. Wall Street Zen cut shares of Zura Bio from a "hold" rating to a "sell" rating in a report on Sunday, November 16th. Chardan Capital reaffirmed a "buy" rating and issued a $10.00 target price on shares of Zura Bio in a research report on Friday, November 14th. Finally, Wedbush initiated coverage on shares of Zura Bio in a research note on Monday, February 9th. They set an "outperform" rating and a $15.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $11.60.
View Our Latest Stock Analysis on ZURA
Zura Bio Company Profile
(
Get Free Report)
Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.
The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
